What Leerink, Wainwright Have To Say For This Alzheimer's Focused Firm

Earlier today, AC Immune SA ACIU announced semorinemab met one of its co-primary endpoints in a mid-stage Alzheimer's disease trial.
SVB Leerink notes that semorinemab data is "good news." It has an Outperform rating on the stock.
Analyst Marc Goodman believes the AD community and investors should appreciate the data.
Overall, the analyst believes the data provides initial clinical validation for the anti-Tau antibody approach for treating AD and incremental proof-of-concept data to support semorinemab's potential efficacy in AD.
H.C. Wainwright notes "encouraging turn of events" for AC Immune's anti-tau antibody. Analyst Andrew Fein believes Alzheimer's trial data showing a 43.6% reduction in cognitive decline is "quite striking."
However, Fein notes that the trial did not meet the second co-primary endpoint, which he believes might relate to the length of the trial.
There were no safety-related issues, which the analyst thinks is positive given the prevalence of ARIA in anti-amyloid therapies.
Wainwright has a Buy rating and a price target of $16 on the stock.
Price Action: ACIU stock is up 18.50% at $8.28 during the market session on the last check Tuesday.

Analyst Calendar